中国神经再生研究(英文版) ›› 2024, Vol. 19 ›› Issue (9): 1984-1990.doi: 10.4103/1673-5374.390955

• 综述:视神经损伤修复保护与再生 • 上一篇    下一篇

生长抑素在糖尿病视网膜病变中的意义

  

  • 出版日期:2024-09-15 发布日期:2024-01-25
  • 基金资助:
    重庆市自然科学基金项目(cstc2020jcyj-msxmX0698,cstc2021jcyjbshX0147)以及重庆市江津区科技局项目(Y2022017)

On implications of somatostatin in diabetic retinopathy

Yanhong Fang1, *, Qionghua Wang1, Youjian Li2, Li Zeng3, Jian Liu4, Kepeng Ou2, *   

  1. 1Department of Ophthalmology, Chongqing University Jiangjin Hospital, Chongqing, China; 2College of Pharmacy, National & Local Joint Engineering Research Center of Targeted and Innovative Therapeutics, IATTI, Chongqing University of Arts and Sciences, Chongqing, China; 3Shandong Provincial Hospital, Shandong Laboratory Animal Center, Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, Shandong Province, China; 4Academic Unit of Ophthalmology, Bristol Medical School, University of Bristol, Bristol, UK
  • Online:2024-09-15 Published:2024-01-25
  • Contact: Yanhong Fang, MS, jjykfang@163.com; Kepeng Ou, PhD, kepeng.ou@cqwu.edu.cn.
  • Supported by:
    This work was supported by the Natural Science Foundation of Chongqing of China, Nos. cstc2020jcyj-msxmX0698 (to YF), cstc2021jcyjbshX0147 (to KO); and a grant from Chongqing Jiangjin District Bureau of Science and Technology, No. Y2022017 (to YF).

摘要:

生长抑素作为一种天然产生的神经保护肽,可在视网膜中抑制兴奋性神经传递,并表现出抗增殖和抗炎作用。为总结生长抑素治疗糖尿病视网膜病变中的进展,此次综述检索了PubMed和Google Scholar数据库在2019年至2023年2月发表的相关研究。研究发现,糖尿病视网膜病变早期视网膜中生长抑素水平下降或失调可导致神经保护不足,进而造成视网膜神经血管单元损伤和微血管损伤。因而,生长抑素可作为糖尿病视网膜病变对抗视网膜神经退行性变的一种潜在药物。生长抑素类似物应用于早期糖尿病视网膜病变治疗的临床前和临床试验已经启动。在一项名为EUROCONDOR的试验中,生长抑素滴眼液对视网膜神经功能障碍的患者表现出神经保护作用,但不能影响糖尿病视网膜病变的发生。总之,生长抑素可能对早期视网膜病变患者有益。为了早期预防糖尿病视网膜病变的发生,从而在重度非增生性糖尿病视网膜病变出现之前挽救视觉功能,还需要解决:a)更新和规范视网膜筛查方案,包括早期神经退行性病变的检测;b)确定哪些患者亚群将从生长抑素及生长抑素类似物补充中受益;c)在高血糖情况下,生长抑素特别是外源性生长抑素类似物与其它视网膜肽的相互作用,以及d)设计具有安全性、可行性、低成本和有效性的给药途径。

https://orcid.org/0000-0002-4145-7344 (Kepeng Ou)

关键词: 糖尿病视网膜病变, 生长抑素, 神经退行性变, 神经保护, 神经炎症, 兴奋性毒性, 氧化应激, 奥曲肽, 神经血管单位, 生长激素, 胰岛素样生长因子, 鸢尾素

Abstract: Somatostatin, a naturally produced neuroprotective peptide, depresses excitatory neurotransmission and exerts anti-proliferative and anti-inflammatory effects on the retina. In this review, we summarize the progress of somatostatin treatment of diabetic retinopathy through analysis of relevant studies published from February 2019 to February 2023 extracted from the PubMed and Google Scholar databases. Insufficient neuroprotection, which occurs as a consequence of declined expression or dysregulation of retinal somatostatin in the very early stages of diabetic retinopathy, triggers retinal neurovascular unit impairment and microvascular damage. Somatostatin replacement is a promising treatment for retinal neurodegeneration in diabetic retinopathy. Numerous pre-clinical and clinical trials of somatostatin analog treatment for early diabetic retinopathy have been initiated. In one such trial (EUROCONDOR), topical administration of somatostatin was found to exert neuroprotective effects in patients with pre-existing retinal neurodysfunction, but had no impact on the onset of diabetic retinopathy. Overall, we concluded that somatostatin restoration may be especially beneficial for the growing population of patients with early-stage retinopathy. In order to achieve early prevention of diabetic retinopathy initiation, and thereby salvage visual function before the appearance of moderate non-proliferative diabetic retinopathy, several issues need to be addressed. These include the needs to: a) update and standardize the retinal screening scheme to incorporate the detection of early neurodegeneration, b) identify patient subgroups who would benefit from somatostatin analog supplementation, c) elucidate the interactions of somatostatin, particularly exogenously-delivered somatostatin analogs, with other retinal peptides in the context of hyperglycemia, and d) design safe, feasible, low cost, and effective administration routes.

Key words: diabetes retinopathy, excitotoxicity, growth hormone, insulin like growth factor, irisin, neurodegeneration, neuroinflammation, neuroprotection, neurovascular unit, octreotide, oxidative stress, somatostatin